Orion Veterinary Medicines and Vetoquinol are expanding their cooperation with new distribution agreements.

In June 2020, the US Food and Drug Administration (FDA) granted a marketing authorization for Orion's Clevor, an eye drop drug designed to induce vomiting in dogs. Under the terms of the product agreement, Vetoquinol will be granted the right to sell and market Clevor (the active ingredient ropinirole) in the United States.

On August 1, 2020, Vetoquinol acquired the rights to Drontal and Profender products in the EU and the UK. Orion will have the right to sell and market Vetoquinol's Drontal and Profender products in Finland, Hungary and Romania as of January 1, 2021. Drontal products are used to repel parasites in cats and dogs and Profender is used to repel parasites in cats.

The new distribution agreements expand the companies' current cooperation, in which Vetoquinol has been a distributor of Orion's sedative product range for veterinary medicines in several European countries since February 2015.

'I am very pleased with the expansion of fruitful cooperation with Vetoquinol, and the fact that we are a trusted partner to distribute Orion latest innovation of veterinary medicines approved in the United States. In addition, it is very important for us to be able to continue selling Drontal and Profender products in our home market in Finland and to expand our distribution to Hungary and Romania as well, 'says Niclas Lindstedt, Director of Veterinary Medicines at Orion.

We are pleased to strengthen our partnership with Orion. Our Drontal and Profender products will benefit from an efficient distribution network in Finland, Hungary and Romania. In addition, Vetoquinol is proud that Orion chose the company to develop the innovative Clevor brand in the United States. This new milestone in our collaboration is a testament to Vetoquinol's ability and knowledge in the pharmaceutical industry in this key market, 'says Matthieu Frechin, CEO of Vetoquinol .

Orion

Orion is a Finnish pharmaceutical company - a builder of well-being that operates worldwide. Orion develops, manufactures and markets human and veterinary medicines as well as active pharmaceutical ingredients. The company constantly invests in research and development of new drugs and treatments. The core therapeutic areas of Orion's pharmaceutical research are neurological diseases, cancer diseases, rare diseases of the Finnish genetic heritage and respiratory diseases, for the treatment of which Orion develops inhaled lung drugs under the Easyhaler device portfolio. Orion's net sales in 2019 were EUR 1,051 million, and the company employed about 3,300 people at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Vetoquinol

Vetoquinol is a leading global veterinary company supplying pharmaceuticals and non-pharmaceutical products to the livestock (cattle and pigs) and pet (dogs and cats) markets. As an independent operator, Vetoquinol designs, develops and sells veterinary and non-pharmaceutical products in more than 100 countries through its 24 subsidiaries in Europe, the Americas and the Asia-Pacific region, as well as its global export unit. Since its inception (1933), Vetoquinol has implemented a strategy that combines innovation and geographical diversity. The driver of the Group's hybrid growth is the strengthening of its own product portfolio combined with acquisitions in high-potential growth markets. Vetoquinol employed 2,401 people at the end of June 2020.

Contact:

Tel: 010 426 4116

(C) 2021 Electronic News Publishing, source ENP Newswire